Back to top
more

Geron (GERN)

(Delayed Data from NSDQ)

$4.14 USD

4.14
24,217,859

+0.35 (9.23%)

Updated Apr 29, 2024 04:00 PM ET

Pre-Market: $4.11 -0.03 (-0.72%) 8:24 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Geron (GERN) Stock Moves -1.78%: What You Should Know

by Zacks Equity Research

In the latest trading session, Geron (GERN) closed at $2.76, marking a -1.78% move from the previous day.

Geron (GERN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors will focus on updates on Geron's (GERN) lead pipeline candidate when it reports its fourth-quarter earnings.

Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adaptive Biotechnologies (ADPT) and Geron (GERN) have performed compared to their sector so far this year.

Geron (GERN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Geron (GERN) closed at $2.69 in the latest trading session, marking a +1.13% move from the prior day.

Geron (GERN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Geron (GERN) closed at $3.01 in the latest trading session, marking a -1.31% move from the prior day.

Geron (GERN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Geron (GERN) closed the most recent trading day at $3.34, moving -1.18% from the previous trading session.

Is Achilles Therapeutics (ACHL) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Geron (GERN) have performed compared to their sector so far this year.

Geron (GERN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Geron (GERN) closed at $3.34, marking a -0.89% move from the previous day.

Are Medical Stocks Lagging COMPASS Pathways (CMPS) This Year?

by Zacks Equity Research

Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and Geron (GERN) have performed compared to their sector so far this year.

The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax

by Zacks Equity Research

Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax are included in this Analyst Blog.

Geron (GERN) Up on Imetelstat Data on Myelodysplastic Syndromes

by Zacks Equity Research

Geron (GERN) posts positive top-line data from the phase III IMerge study investigating its lead candidate, imetelstat for treating lower risk myelodysplastic syndromes. Shares up.

Biotech Stock Roundup: GERN Surges on Study Data, PHAT, VERA Offer Updates & More

by Zacks Equity Research

Updates from Geron (GERN) and VERA are the key highlights from the biotech sector during the past week.

Novavax (NVAX) Down 7.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Axsome (AXSM) Up 18.6% Since Last Earnings Report?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Geron (GERN) delivered earnings and revenue surprises of -11.11% and 156.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Geron (GERN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Geron (GERN) and Kiniksa Pharmaceuticals, Ltd. (KNSA) have performed compared to their sector so far this year.

J&J (JNJ) to Stop Selling Talc-based Baby Powder From 2023

by Zacks Equity Research

J&J (JNJ) will stop selling its talcum-based baby powder globally from next year. Though reports claim that the use of the talc causes cancer, JNJ maintains its stance that this product is safe.

Karuna (KRTX) Stock Skyrockets 98.7% in a Month: Here's Why

by Zacks Equity Research

Karuna Therapeutics (KRTX) is progressing well with its pipeline development. KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.

Allogene (ALLO) Q1 Earnings Beat, Pipeline Progressing Well

by Zacks Equity Research

Allogene's (ALLO) second-quarter earnings beat estimates. ALLO is on track to initiate a pivotal phase II study on ALLO-501A in large B cell lymphoma in the coming weeks.

Perrigo's (PRGO) Q2 Earnings Misses by a Cent, Sales Beat

by Zacks Equity Research

Perrigo (PRGO) delivers mixed second-quarter 2022 results. Higher demand for cough/cold products continues during the reported quarter. Unfavorable currency movements hurt sales and earnings.

Karuna (KRTX) Lags on Q2 Earnings, Up 71% on Schizophrenia Data

by Zacks Equity Research

Though Karuna's (KRTX) earnings miss estimates, KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.

Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of 16% and 2.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Immunovant (IMVT) Loss Narrows in Q1, Focus on Batoclimab

by Zacks Equity Research

Immunovant's (IMVT) earnings beat estimates in the fiscal first quarter ended on Jun 30, 2022. The company is evaluating batoclimab in a pivotal study for treating myasthenia gravis.

All You Need to Know About Geron (GERN) Rating Upgrade to Strong Buy

by Zacks Equity Research

Geron (GERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

VERU's Shares Jump on Successful COVID-19 Study Results

by Zacks Equity Research

VERU gains on the success of its late stage study evaluating the efficacy and safety of oral sabizabulin 9 mg for COVID-19.